Free Trial
One Day Left! MarketBeat All Access Returns to $249 Soon
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Don't Miss Out
Claim MarketBeat All Access Sale Promotion

Citigroup's Rating of BR Biopharma on 10/27/2026

On October 27, 2026, Citigroup updated its outlook on BR Biopharma (NASDAQ:BRBI) with the action "Downgrade", setting a "Hold" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Citigroup Inc.

DateCompanyAction
10/29/2026
eBay Inc. stock logo
EBAY
eBay
Downgrade
10/29/2026
Nextpower Inc. stock logo
NXT
Nextpower
Reiterated Rating
10/29/2026
IDEX Corporation stock logo
IEX
IDEX
Boost Price Target
10/29/2026
Bloom Energy Corporation stock logo
BE
Bloom Energy
Boost Price Target
10/29/2026
Noble Corporation PLC stock logo
NE
Noble
Boost Price Target
10/29/2026
RenaissanceRe Holdings Ltd. stock logo
RNR
RenaissanceRe
Boost Price Target
More Ratings From Citigroup Inc.